Deborah A Zarin is featured in “Patient hopes dashed as FDA fails to tackle hidden clinical trial results” in Transparimed.
Read now >
Deborah A. Zarin is featured in STAT’s Pharmalot’s “FDA finalizes penalties for clinical trial sponsors that don’t share data, but critics say they fall short.”
Read article >
Published on: July 31, 2020
Published by: National Academies of Sciences, Engineering, and Medicine
“COVID Trials Threatened by Shifting Surges” — MRCT Center Faculty Director, Dr. Barbara E. Bierer, discussed the state of clinical trials in the COVID-19 era, the need for clinical trial networks to be in place beforehand to speed broad multisite collaborations and the benefit of the COVID-19 Collaboration Platform in MedPageToday.
MRCT Center Program Director, Deborah A. Zarin contributed to STAT’s The Pharmalot View “Where’s the data? In a pandemic, now is no time to sit on Covid-19 trial results.”
Comments provided on: April 29, 2020
Comments provided to : European Commission
Diagnostic tests for COVID-19 are central to most proposed plans for relaxing physical distancing and related policies.
The following work by Deborah A. Zarin, MD MRCT Center Program Director and Joseph Lau, MD ,Professor Emeritus of Health Services, Policy and Practice, Center for Evidence Synthesis in Health, Brown University School of Public Health serves as a reminder about what we know and don’t know about these tests, how frequently they might produce inaccurate results, and how these inaccuracies might affect their utility in different potential scenarios. Read Paper >
Published on: March 20, 2020
Published in: Science
